



上海源叶生物科技有限公司  
 Shanghai yuanye Bio-Technology Co., Ltd  
 电话: 021-61312973 传真: 021-55068248  
 网址: www.shyuanye.com  
 邮箱: shyysw@sina.com

产品名称: **Topiroxostat**  
 产品别名: 托匹司他; **FYX-051**

生物活性:																										
<b>Description</b>	Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment[1][2].																									
<b>IC<sub>50</sub> &amp; Target</b>	IC50: 5.3 nM (XOR)[1] Ki: 5.7 nM (XOR)[2]																									
<b>In Vitro</b>	These potent and more sustained effects of Topiroxostat (FYX-051, compound 39) have been confirmed by a crystallographic analysis of XOR-Topiroxostat complex. The cyano group of Topiroxostat has been reported to play an important role in the binding activity between Topiroxostat and XOR. This is attributable to the formation of a hydrogen bond between Asn 768 of XOR and the cyano group of Topiroxostat[1].																									
<b>In Vivo</b>	Topiroxostat (FYX-051; 0.03-10 mg/kg; oral administration; for 1 hour; male Wistar/ST strain rats) treatment shows a potent and long-lasting hypouricemic effect in a rat model of potassium oxonate-induced hyperuricemia[2].  The C <sub>max</sub> and bioavailability of Topiroxostat (FYX-051, compound 39) are as high as 4.62 µg/mL (3 mg/kg) and 69.6%, respectively. Moreover, the t <sub>1/2</sub> value of Topiroxostat is 19.7 hours[1].																									
	<b>Animal Model:</b> Male Wistar/ST strain rats (7 weeks old) injected with potassium oxonate[2]																									
	<b>Dosage:</b> 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg																									
	<b>Administration:</b> Oral administration; for 1 hour																									
	<b>Result:</b> Caused a dose-dependent decrease in serum urate levels with an extremely low ED <sub>50</sub> of 0.15 mg/kg, evaluated at 1 h after oral administration.																									
<b>Solvent&amp;Solubility</b>	<b>In Vitro:</b> DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)																									
	<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="2">Solvent</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th>Mass</th> <th>Concentration</th> </tr> </thead> <tbody> <tr> <td><b>Preparing</b></td> <td>1 mM</td> <td></td> <td>4.0284 mL</td> <td>20.1418 mL</td> <td>40.2836 mL</td> </tr> <tr> <td rowspan="2"><b>Stock Solutions</b></td> <td>5 mM</td> <td></td> <td>0.8057 mL</td> <td>4.0284 mL</td> <td>8.0567 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.4028 mL</td> <td>2.0142 mL</td> <td>4.0284 mL</td> </tr> </tbody> </table>		Solvent		1 mg	5 mg	10 mg	Mass	Concentration	<b>Preparing</b>	1 mM		4.0284 mL	20.1418 mL	40.2836 mL	<b>Stock Solutions</b>	5 mM		0.8057 mL	4.0284 mL	8.0567 mL	10 mM		0.4028 mL	2.0142 mL	4.0284 mL
			Solvent					1 mg	5 mg	10 mg																
		Mass	Concentration																							
<b>Preparing</b>	1 mM		4.0284 mL	20.1418 mL	40.2836 mL																					
<b>Stock Solutions</b>	5 mM		0.8057 mL	4.0284 mL	8.0567 mL																					
	10 mM		0.4028 mL	2.0142 mL	4.0284 mL																					
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。																										
<b>References</b>	[1]. Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.  [2]. Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103.																									